Industry Updates
A great extended interview about how rare disease foundations are partnering with biotechs, providing seed funding and helping organize eager trial participants to bring new therapies to market. Also note the personalized medicine aspect of this story; VX-770 and VX-809 are targetted specifically at patients who express the G551D mutation as root cause for their [...]
Industry Updates
More creative biotech funding, this time from Boston-based Vertex to develop and market their Hepatitis C protease inhibitor Telaprevir. Mitsubishi Tanabe Pharma is putting $105M of its money where its mouth is for the rights to market this potential blockbuster in Asia.
http://www.xconomy.com/boston/2009/07/30/vertex-grabs-105m-in-amended-telaprevir-deal-with-mitsubishi/
Industry Updates
Vertex, a Boston-based biotech with offices in San Diego, announces clinical trials of their new Cystic Fibrosis drug. It will be exciting to see how these go.
Cystic Fibrosis, an abnormality to a protein that regulates chloride ions in cells, is one of the most common genetic conditions in our population, and often shows up in [...]